Prestige Consumer Healthcare In found using ticker (PBH) now have 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 72 and 60 calculating the average target price we see 67.6. Now with the previous closing price of 57.66 this is indicating there is a potential upside of 17.2%. The 50 day moving average now sits at 57.78 and the 200 moving average now moves to 57.61. The company has a market capitalisation of $2,846m. Find out more information at: https://www.prestigebrands.com
The potential market cap would be $3,337m based on the market concensus.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody’s analgesic powders, Boudreaux’s Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden’s cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer’s Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
